Pirisudanol

Pirisudanol

SCHEMBL49261

Cc1ncc(COC(=O)CCC(=O)OCCN(C)C)c(CO)c1O

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
HPGD P15428 3/20 0.49
KDM4E B2RXH2 2/20 0.49
HSD17B10 Q99714 1/20 0.49
LMNA P02545 3/20 0.40
HDAC1 Q13547 2/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP2D6 P10635 1/20 0.37
HIF1A Q16665 1/20 0.37
DNM1 Q05193 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
AOX1 Q06278 1/20 0.36
TRIM24 O15164 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP3A4 P08684 1/20 0.36
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pirisudanol SCHEMBL1650884 0.94 HPGD (0.43) ALDH1A1HPGDKDM4EHSD17B10LMNA
Pirisudanol SCHEMBL6376757 0.94 HPGD (0.43) ALDH1A1HPGDKDM4EHSD17B10LMNA
Pirisudanol SCHEMBL28086569 0.82 APEX1 (0.41) ALDH1A1HPGDKDM4EHSD17B10LMNA
SCHEMBL5346682 0.81 KDM4E (0.61) ALDH1A1HPGDKDM4EHSD17B10LMNA
SCHEMBL478873 0.80 KDM4E (0.52) ALDH1A1HPGDKDM4EHSD17B10LMNA
SCHEMBL9232006 0.79 KDM4E (0.51) ALDH1A1HPGDKDM4EHSD17B10LMNA
SCHEMBL29387458 0.79 KDM4E (0.51) ALDH1A1HPGDKDM4EHSD17B10LMNA
SCHEMBL516267 0.79 KDM4E (0.51) ALDH1A1HPGDKDM4EHSD17B10LMNA
SCHEMBL49262 0.76 HPGD (0.45) ALDH1A1HPGDKDM4EHSD17B10LMNA
SCHEMBL27334611 0.75 SGPL1 (0.41) ALDH1A1HPGDKDM4EHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
CN-102275053-B Welding robot system GUANGZHOU AUTOMOBILE GROUP PASSENGER CARS CO LTD 2014-12-03 CN claimed
EP-2560634-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS Piramal Enterprises Limited (IN) 2013-02-27 EP claimed
WO-2012116278-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2012-08-30 WO claimed
CN-102275053-A Welding robot system 2011-12-14 CN claimed
WO-2011132171-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 WO claimed
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 US claimed
US-20100233112-A1 SHAPE MEMORY POLYMER NETWORK USING HETEROCYCLIC GROUPS THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2010-09-16 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101484152-A Therapeutic combination for painful medical conditions SANOL ARZNEI SCHWARZ GMBH (DE) 2009-07-15 CN claimed
WO-2007141018-A1 THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS SCHWARZ PHARMA AG (DE) 2007-12-13 WO claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20070043120-A1 Therapeutic combination for painful medical conditions UCB PHARMA GMBH (DE) 2007-02-22 US claimed
US-20070042969-A1 Combination therapy for pain in painful diabetic neuropathy SRZ PROPERTIES, INC. (US) 2007-02-22 US claimed
EP-1725222-A2 METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS Pharmacia Corporation (US) 2006-11-29 EP claimed
WO-2005084654-A2 METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS PHARMACIA CORPORATION (US) 2005-09-15 WO claimed
US-5780055-A BEAD PREPARED FROM MICROCRYSTALLINE CELLULOSE BY EXTRUSION-SPHERONIZATION AND FREEZE DRYING UNIVERSITY OF MARYLAND, BALTIMORE (US) 1998-07-14 US claimed
WO-1998009597-A2 CUSHIONING BEADS AND TABLET COMPRISING THE SAME CAPABLE OF FORMING A SUSPENSION UNIVERSITY OF MARYLAND BALTIMORE (US) 1998-03-12 WO claimed
EP-0116238-A1 Therapeutic compositions and their use in enhancing brain function BIOMEASURE, INC. (US) 1984-08-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042969-A1 Combination therapy for pain in painful diabetic neuropathy GRIN2B, GRIN2A, GRIN3A ALDH1A1 2350/4885HPGD 1595/4885KDM4E 1053/4885
US-20100233112-A1 SHAPE MEMORY POLYMER NETWORK USING HETEROCYCLIC GROUPS H1-4, PNN, CD44 ALDH1A1 4283/4885HPGD 56/4885KDM4E 2759/4885
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents NOS2, NOS1, NOS3 ALDH1A1 204/4885HPGD 9/4885KDM4E 2388/4885
US-20070043120-A1 Therapeutic combination for painful medical conditions PDE1B, CA2, CACNA1S ALDH1A1 2182/4885HPGD 790/4885KDM4E 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.